ERBB2 and breast cancer: Western blot analysis revealed that both Lapatinib and Broussoflavonol B were able to disrupt the ER-α36-EGFR/HER2 regulatory loops in the breast cancer stem/progenitor cells derived from MCF7/TAM cells (Figure 6B).